BACKGROUND AND OBJECTIVES: Cognitive impairment is common among persons with ESRD, but the underlying mechanisms are unknown. This study evaluated the prevalence of cognitive impairment and association with modifiable ESRD- and dialysis-associated factors in a large group of hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Cross-sectional analyses were conducted on baseline data collected from 383 subjects participating in the Frequent Hemodialysis Network trials. Global cognitive impairment was defined as a score <80 on the Modified Mini-Mental State Exam, and impaired executive function was defined as a score >or=300 seconds on the Trailmaking B test. Five main categories of explanatory variables were examined: urea clearance, nutritional markers, hemodynamic measures, anemia, and central nervous system (CNS)-active medications. RESULTS: Subjects had a mean age of 51.6 +/- 13.3 years and a median ESRD vintage of 2.6 years. Sixty-one subjects (16%) had global cognitive impairment, and 110 subjects (29%) had impaired executive function. In addition to several nonmodifiable factors, the use of H1-receptor antagonists and opioids were associated with impaired executive function. No strong association was found between several other potentially modifiable factors associated with ESRD and dialysis therapy, such as urea clearance, proxies of dietary protein intake and other nutritional markers, hemodynamic measures, and anemia with global cognition and executive function after adjustment for case-mix factors. CONCLUSIONS: Cognitive impairment, especially impaired executive function, is common among hemodialysis patients, but with the exception of CNS-active medications, is not strongly associated with several ESRD- and dialysis-associated factors.
BACKGROUND AND OBJECTIVES:Cognitive impairment is common among persons with ESRD, but the underlying mechanisms are unknown. This study evaluated the prevalence of cognitive impairment and association with modifiable ESRD- and dialysis-associated factors in a large group of hemodialysis patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Cross-sectional analyses were conducted on baseline data collected from 383 subjects participating in the Frequent Hemodialysis Network trials. Global cognitive impairment was defined as a score <80 on the Modified Mini-Mental State Exam, and impaired executive function was defined as a score >or=300 seconds on the Trailmaking B test. Five main categories of explanatory variables were examined: urea clearance, nutritional markers, hemodynamic measures, anemia, and central nervous system (CNS)-active medications. RESULTS: Subjects had a mean age of 51.6 +/- 13.3 years and a median ESRD vintage of 2.6 years. Sixty-one subjects (16%) had global cognitive impairment, and 110 subjects (29%) had impaired executive function. In addition to several nonmodifiable factors, the use of H1-receptor antagonists and opioids were associated with impaired executive function. No strong association was found between several other potentially modifiable factors associated with ESRD and dialysis therapy, such as urea clearance, proxies of dietary protein intake and other nutritional markers, hemodynamic measures, and anemia with global cognition and executive function after adjustment for case-mix factors. CONCLUSIONS:Cognitive impairment, especially impaired executive function, is common among hemodialysis patients, but with the exception of CNS-active medications, is not strongly associated with several ESRD- and dialysis-associated factors.
Authors: R S Suri; A X Garg; G M Chertow; N W Levin; M V Rocco; T Greene; G J Beck; J J Gassman; P W Eggers; R A Star; D B Ornt; A S Kliger Journal: Kidney Int Date: 2006-12-13 Impact factor: 10.612
Authors: Arema A Pereira; Daniel E Weiner; Tammy Scott; Priya Chandra; Robyn Bluestein; John Griffith; Mark J Sarnak Journal: Hemodial Int Date: 2007-07 Impact factor: 1.812
Authors: Christopher B Brady; J Michael Gaziano; Roberta A Cxypoliski; Peter D Guarino; James S Kaufman; Stuart R Warren; Pamela Hartigan; David S Goldfarb; Rex L Jamison Journal: Am J Kidney Dis Date: 2009-07-23 Impact factor: 8.860
Authors: Miranda T Schram; Sjoerd M Euser; Anton J M de Craen; Jacqueline C Witteman; Marijke Frölich; Albert Hofman; Jelle Jolles; Monique M B Breteler; Rudi G J Westendorp Journal: J Am Geriatr Soc Date: 2007-05 Impact factor: 5.562
Authors: Anne M Murray; Sarah L Pederson; David E Tupper; Angela K Hochhalter; Wendy A Miller; Qi Li; David Zaun; Allan J Collins; Robert Kane; Robert N Foley Journal: Am J Kidney Dis Date: 2007-08 Impact factor: 8.860
Authors: Vladimir Hachinski; Costantino Iadecola; Ron C Petersen; Monique M Breteler; David L Nyenhuis; Sandra E Black; William J Powers; Charles DeCarli; Jose G Merino; Raj N Kalaria; Harry V Vinters; David M Holtzman; Gary A Rosenberg; Anders Wallin; Martin Dichgans; John R Marler; Gabrielle G Leblanc Journal: Stroke Date: 2006-08-17 Impact factor: 7.914
Authors: Mary Hannan; Alana Steffen; Lauretta Quinn; Eileen G Collins; Shane A Phillips; Ulf G Bronas Journal: J Nephrol Date: 2018-05-25 Impact factor: 3.902
Authors: Eric P Sorensen; Mark J Sarnak; Hocine Tighiouart; Tammy Scott; Lena M Giang; Bethany Kirkpatrick; Kristina Lou; Daniel E Weiner Journal: Am J Kidney Dis Date: 2012-03-15 Impact factor: 8.860
Authors: Ann M O'Hare; Rod Walker; Sebastian Haneuse; Paul K Crane; Wayne C McCormick; James D Bowen; Eric B Larson Journal: J Am Geriatr Soc Date: 2012-12 Impact factor: 5.562
Authors: Meera N Harhay; Dawei Xie; Xiaoming Zhang; Chi-Yuan Hsu; Eric Vittinghoff; Alan S Go; Stephen M Sozio; Jacob Blumenthal; Stephen Seliger; Jing Chen; Rajat Deo; Mirela Dobre; Sanjeev Akkina; Peter P Reese; James P Lash; Kristine Yaffe; Manjula Kurella Tamura Journal: Am J Kidney Dis Date: 2018-05-02 Impact factor: 8.860